Loading...
In the past week, NEJM Journal Watch and Physician's First Watch have brought you coverage of study findings presented at the American College of Cardiology's annual Scientific Session, held this year in New Orleans. Here is a compilation of our coverage, listed by date and title of meeting presentations, with the articles' first authors in parentheses.
(Your NEJM Journal Watch subscription is required, except where noted.)
Monday, March 18, 2019
COACT Trial: Coronary Angiography after Cardiac Arrest (Lemkes JS et al.)
TREAT Trial: Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction (Berwanger O et al.)
CREOLE Study: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (Ojji DB et al.)
Sunday, March 17, 2019
PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results of the PARTNER 3 Trial (Mack MJ et al.)
Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality (Popma JJ et al.)
AUGUSTUS Trial: An Open-label, 2 x 2 Factorial, Randomized Trial to Evaluate the Safety of Apixaban versus Vitamin K Antagonist and Aspirin versus Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention: Primary Results of the AUGUSTUS Trial (Lopes RD et al.)
MOMENTUM 3: Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3: Final Analysis of the 1028 Patient Cohort Outcomes (Mehra MR et al.)
POET: Partial Oral Treatment of Left-Sided Infectious Endocarditis — The POET Trial — Long Term Follow-up (Bundgaard H et al.)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (Arnett DK et al.)
Physician's First Watch coverage (free)
Misclassification of Myocardial Injury as Type 2 Myocardial Infarction and Implications For 30-Day Outcomes (McCarthy C et al.)
First Randomized Human Experience with a Ticagrelor Reversal Agent (Bhatt DL et al.)
WRAP-IT: The World-Wide Randomized Antibiotic Envelope Infection Prevention Trial to Reduce Cardiac Implantable Electronic Device Infection (Tarakji KG et al.)